An overview of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for the anesthesiologist.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23460568.
- Also identified by DOI 10.1213/ANE.0b013e3182860fff.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Anesthesiologists face several perioperative challenges when patients need cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion. To adequately care for these patients, anesthesiologists must understand the goals and objectives of the operation in addition to having a basic knowledge of the chemotherapeutic drugs that are frequently used. Optimal anesthetic management of patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion requires control of a complex interplay of physiologic mechanisms, including hyperthermia, abdominal hypertension, electrolyte abnormalities, coagulopathies, increased cardiac index, oxygen consumption, and decreased systemic vascular resistance. As this surgery continues to gain popularity among oncologic surgeons, further studies that clearly define the chemistry, pharmacokinetics, pharmacodynamics, and end points of efficacy need to be performed to elucidate optimal perioperative management.
Medical subject headings
- Anesthesia
- Antineoplastic Agents
- Chemotherapy, Cancer, Regional Perfusion
- Peritoneal Neoplasms